As the gene therapy landscape rapidly evolves, so too must the tools that power its progress. Recombinant adeno-associated viruses (rAAVs) are the vectors of choice for many groundbreaking therapies—but scalable, high-quality production remains a major bottleneck.

In this white paper, NewBiologix introduces Xcell™ Eng-HEK293, a GMP-ready, suspension-adapted, serum-free clonal HEK293 cell line specifically engineered for efficient and flexible rAAV production. Whether you're in early-stage development or scaling for commercial manufacturing, Xcell Eng-HEK293 delivers consistent performance across media types, bioreactor platforms, and production volumes

What You’ll Learn in This White Paper

✅ Why Xcell™ Eng-HEK293 is a Game-Changer for rAAV Manufacturing
 Understand how a purpose-built, clonal HEK293 line outperforms legacy cell lines in flexibility, robustness, and rAAV quality.
✅ Performance Across Commercial Media Formulations
 See data from head-to-head comparisons of Xcell Eng-HEK293 in multiple GMP-ready, off-the-shelf media, including VPM, HyClone, Cellvento, and more.
✅ Scalability from Bench to Bioreactor
 Discover how Xcell Eng-HEK293 maintains consistent vector yields and quality across a wide range of culture volumes—from 0.75 ml to 10 L.
✅ Bioreactor Flexibility to Fit Any Facility
 Learn how this cell line adapts seamlessly to orbital shakers, wave rockers, and stirred-tank systems, enabling easier tech transfer and process standardization.
✅ Clinical-Grade Vector Production with Therapeutic Transgenes
 Review case studies of large-scale rAAV production using clinically relevant payloads, supporting real-world CDMO and commercial applications.